| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780847 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
HDR-IGBT alone for treatment of early-stage, medically inoperable endometrial cancer is feasible with excellent response rates and clinical results. This approach also allows sparing of critical organs and ensures target coverage, which contributed to the low toxicity rate and high LRC in comparison with 2D point-based series.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Brian Gebhardt, Beant Gill, Scott Glaser, Hayeon Kim, Chris Houser, Joseph Kelley, Paniti Sukumvanich, Robert Edwards, John Comerci, Alexander Olawaiye, Madeleine Courtney-Brooks, Michelle Boisen, Jessica Berger, Sushil Beriwal,